Shuttle Pharmaceuticals Holdings, Inc.

What they do

The company historically developed Ropidoxuridine, its lead radiation-sensitizer product candidate, but committed on November 20, 2025 to wind down those clinical trials. On November 21, 2025 it acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company building an AI platform for molecular discovery and early-stage drug development. Molecule.ai offers a unified inference engine, an API-first integration layer and a modular model framework supporting molecular property prediction, cross-molecule and cross-property evaluation, and prediction reasoning. The company reported no revenues for the year ended December 31, 2025.

Revenue drivers

• Molecule.ai platform licensing — The AI molecular discovery platform is the company's stated commercial focus, but no platform revenue was reported for the year ended December 31, 2025. Management flags the risk that failure to acquire and retain customers, or customer renewals at lower prices, would hurt future revenues.
• Legacy Ropidoxuridine program — Ropidoxuridine, the prior lead product candidate, was the historical drug-development focus. The company committed to a plan to wind down its clinical trials on November 20, 2025, so this program is not a forward revenue source.
• Planned Molecule.ai module expansion — Molecule.ai is expanding into chemical-protein interaction likelihoods, biological context reasoning using curated genomic and disease-association evidence, and an autonomous AI agent. These are described as development efforts, not currently revenue-generating products.

Recent performance

Net loss widened every year from approximately $1.2 million in 2021 to approximately $11.7 million in 2025, with no revenues reported for 2025. Operating cash flow was negative each year, deteriorating from about $0.3 million used in 2021 to about $9.5 million used in 2025. Diluted EPS was $-7.16 in 2025 versus $-82.60 in 2024, a figure affected by share-count changes. As of March 31, 2026, total assets were $11.8 million, total liabilities $8.5 million, shareholder equity $3.3 million and cash and equivalents $1.1 million. Intangible assets of $9.2 million at March 31, 2026, tied to the Molecule.ai asset acquisition, represent the bulk of total assets.

Strategy

The stated direction is to leverage Molecule.ai's molecular modeling and predictive analytics platform to augment drug discovery and development, while winding down the Ropidoxuridine clinical trials. Molecule.ai is being expanded with new modules for chemical-protein interaction likelihoods, biological context reasoning and an autonomous AI agent intended to plan, route and iterate discovery tasks. Management says the platform aims to become a foundational AI layer for molecular and biological reasoning in pharmaceutical research and development. The company holds $4.4 million of consideration payable and a $2.0 million contingent consideration liability tied to the Molecule.ai acquisition. Its stated near-term priority is raising additional equity or debt financing to fund operations.

Risks

• Going concern — The company has incurred losses since inception, had a net loss of approximately $11.7 million and no revenues for 2025, and a working capital deficit of approximately $7.5 million at December 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Customer and pricing risk on Molecule.ai — Management states that failure to acquire and retain customers for the Molecule.ai platform, or customer renewals at lower prices, would negatively impact future revenues.
• Acquisition integration and benefit risk — The Molecule.ai asset purchase and any future acquisitions may expose the company to inability to realize intended benefits, acquisition costs, or loss of and harm to key personnel.
• Internal controls — Management has determined that the company's internal controls were deemed to be inadequate, and says it is working to improve them.

Outlook

Management states that the ability to continue as a going concern depends on successfully raising additional equity or debt financing to fund operations. The company's stated forward work is expanding the Molecule.ai platform, including a chemical-protein interaction module, biological context reasoning and an autonomous AI agent. No revenue guidance or profitability timeline is provided in the excerpts, and the company reported no revenues for 2025.